Dr. Ben Wolozin, M.D., Ph.D., CSO and co-founder of Aquinnah Pharmaceuticals, pioneered the groundbreaking connection between stress granules and neurodegenerative diseases — a discovery now recognized as one of the most important in the field, offering a beacon of hope for patients and their families. Aquinnah technology leverages its extensive expertise in unraveling the intricate interplay of RNA-binding proteins to form biomolecular condensates, such as stress granules. Aquinnah is strategically targeting its technology to remove the pathologic biomolecular condensates (containing particularly “sticky” proteins) that contribute to disease progression in Amyotrophic "Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, Alzheimer’s disease, and other neurological disorders.

Our profound understanding of this biological landscape has empowered us to identify and develop new innovative small molecule therapeutics, administered as a pill, to address the pressing unmet medical needs for effective neurodegenerative disease treatments.

The robust foundation of our scientific approach is forged through a longstanding commitment to neurodegenerative research, unwavering standards, and a pioneering, out-of-the-box mindset. We've garnered support from major pharmaceutical companies including Abbvie, Pfizer, and Takeda, in addition to securing numerous peer-reviewed grants from the National Institute of Health and other leading foundations supporting innovative brain research.

While neurodegenerative drug development traditionally carries inherent risks, our seasoned and successful drug discovery and development team has made remarkable progress, introducing novel strategies to surmount these challenges and transform possibilities into realities.